Background: Cardiovascular disease (CVD) and metabolic syndrome (MS) have become more prevalent among the HIV-infected patients. The purpose of this study is to describe the prevalence and characteristics of MS among the HIV-infected patients.
Methods: All patients attending the HIV clinic in University of Malaya Medical Centre from July 2011until January 2012 were included. Patients with symptomatic HIV, established coronary heart disease, hypertension, dyslipidaemia and diabetes mellitus were excluded from the study. Patients were examined for blood pressure and anthropometric measurements. History of tobacco consumption, family history of CVD and history of exposure to highly active antiretroviral treatment (HAART) were also obtained. Biochemical analysis comprises oral glucose tolerance test, full lipid profiles (after a 10-hour fasting), CD4 cell counts and HIV RNA viral load. MS was confirmed using the Harmonized criteria (2009).
Results: 126 patients were enrolled in this study. 109 (86.5%) were on HAART and 17 (13.5%) were HAART-naive. Prevalence of MS observed among the HIV-infected patients was 32.5%. The prevalence increased from 19.4% among the HIV-infected patients under age 40 years to 43.8% for those aged more than 40 (p = 0.02). HIV-infected patients with MS were more likely to be male (OR = 3.1; 95% CI:1.2-8.2) and have higher mean body mass index (BMI) (26.3 + 5.0 kg/m2; p < 0.05). Higher prevalence of MS observed in patients on HAART than HAART-naive, 33% and 29% respectively. Patients on HAART with MS were noted to have higher mean age (42.5 + 8.5, p < 0.05) and lower BMI (mean = 23.3 + 3.1 kg/m2; p < 0.05) compared to HAART-naive with MS. Total cholesterol and HDL-c were (5.3 + 1.0 mmol/L) and (1.3 + 0.3 mmol/L) respectively (p < 0.05). Duration of HAART was not a significant factor for MS. When individual HAART was analyzed Ritonavir contributes to MS (OR = 3.2; p = 0.045).
Conclusion: There is high prevalence of MS among HIV-infected patients in Malaysia. Exposure to Ritonavir may increase the risk of developing MS. These study findings highlight the importance of implementing targeted measures in preventing CVD among HIVinfected patients.
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